92 related articles for article (PubMed ID: 17147006)
1. Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: a decision analysis.
Shermock KM; Gildea TR; Singer M; Stoller JK
COPD; 2005 Dec; 2(4):411-8. PubMed ID: 17147006
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency.
Gildea TR; Shermock KM; Singer ME; Stoller JK
Am J Respir Crit Care Med; 2003 May; 167(10):1387-92. PubMed ID: 12574076
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
[TBL] [Abstract][Full Text] [Related]
4. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.
König HH; Barry JC
Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978
[TBL] [Abstract][Full Text] [Related]
6. Screening individuals with intracranial aneurysms for abdominal aortic aneurysms is cost-effective based on estimated coprevalence.
Ball BZ; Jiang B; Mehndiratta P; Stukenborg GJ; Upchurch GR; Meschia JF; Worrall BB; Southerland AM
J Vasc Surg; 2016 Sep; 64(3):811-818.e3. PubMed ID: 27565600
[TBL] [Abstract][Full Text] [Related]
7. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
Inadomi JM; Sampliner R; Lagergren J; Lieberman D; Fendrick AM; Vakil N
Ann Intern Med; 2003 Feb; 138(3):176-86. PubMed ID: 12558356
[TBL] [Abstract][Full Text] [Related]
8. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
10. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
Ferguson TW; Tangri N; Tan Z; James MT; Lavallee BDA; Chartrand CD; McLeod LL; Dart AB; Rigatto C; Komenda PVJ
Kidney Int; 2017 Jul; 92(1):192-200. PubMed ID: 28433383
[TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese.
Xie F; Luo N; Blackhouse G; Goeree R; Lee HP
Int J Technol Assess Health Care; 2008; 24(1):87-95. PubMed ID: 18218173
[TBL] [Abstract][Full Text] [Related]
13. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and population outcomes of general population screening for hepatitis C.
Coffin PO; Scott JD; Golden MR; Sullivan SD
Clin Infect Dis; 2012 May; 54(9):1259-71. PubMed ID: 22412061
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of screening for asymptomatic carotid stenosis.
Yin D; Carpenter JP
J Vasc Surg; 1998 Feb; 27(2):245-55. PubMed ID: 9510279
[TBL] [Abstract][Full Text] [Related]
16. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
Blake GJ; Ridker PM; Kuntz KM
Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
[TBL] [Abstract][Full Text] [Related]
17. The cost-utility of screening for depression in primary care.
Valenstein M; Vijan S; Zeber JE; Boehm K; Buttar A
Ann Intern Med; 2001 Mar; 134(5):345-60. PubMed ID: 11242495
[TBL] [Abstract][Full Text] [Related]
18. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of screening immigrants for hepatitis B.
Wong WW; Woo G; Jenny Heathcote E; Krahn M
Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
[TBL] [Abstract][Full Text] [Related]
20. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
